A Phase 2 Study of Belantamab Mafodotin in People With Lymphoma

Full Title

A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-Cell Lymphoma

Purpose

The purpose of this study is to see if belantamab mafodotin is a useful treatment for lymphoma. The people in this study have plasmablastic lymphoma or ALK-positive large B-cell lymphoma that keeps growing even with treatment.

Belantamab mafodotin is made up of an antibody and a chemotherapy drug. The antibody binds to BCMA, a protein on the surface of cancer cells. Then the chemotherapy enters the cells, which can kill them. Belantamab mafodotin is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have plasmablastic lymphoma or ALK-positive large B-cell lymphoma that keeps growing or came back after treatment.
• Have completed prior lymphoma treatment at last 2 weeks before getting belantamab mafodotin.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Andrew Zelenetz’s office at 646-608-3728.